Разрешен к применению с 1995 года.
Видео о
Купить в
COVID-19 
По алфавиту
N Vey, D Blaise, P Tiberghien, M Attal, J L Pico, J Reiffers, J L Harrousseau, D Fiere, A Tabilio, R Gabus, M Brandely, D Maraninchi
A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomasLeuk Lymphoma. 1996 Mar;21(1-2):107-14.
Nagashima S, Kashii Y, Reichert TE, Suminami Y, Suzuki T, Whiteside TL.
Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo.Int J Cancer. 1997 Jul 3;72(1):174-83. doi: 10.1002/(sici)1097-0215(19970703)72:1<174::aid-ijc25>3.0.co;2-i. PMID: 9212240.
Nagashima S, Mailliard R, Kashii Yet al.
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo.Blood. 1998 May 15;91(10):3850-61. PMID: 9573023.
Nagashima S, Reichert TE, Kashii Y et al.
In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.Cancer Gene Ther. 1997 Nov-Dec;4(6):366-76. PMID: 9408607.
Nagler A, Berger R, Ackerstein A. et al.
A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.J Immunother. 2010 Apr;33(3):326-33.
Najaf Khosravi H, Razi S, Rezaei N.
The role of interleukin-2 in graft-versus-host disease pathogenesis, prevention and therapy.Cytokine. 2024 Nov;183:156723. doi: 10.1016/j.cyto.2024.156723. Epub 2024 Aug 21. PMID: 39173281.
Nelson A, Riise R, Alsén S, et al. 
PDF
Phase I trial of locoregional administration of autologous tumor-infiltrating lymphocytes in patients with uveal melanoma and liver metastases (the HAITILS trial).
Journal for ImmunoTherapy of Cancer 2026;14:e014401. doi:10.1136/jitc-2025-014401
Nie Wenjuan, Yang Yang, Shi Wenhui et al.
Treatment containing interleukin-2 may improve the early sputum culture negative conversion rate in newly diagnosed and drug-susceptible pulmonary tuberculosis patients.Chinese Journal of Antituberculosis. — 2022. — Vol. 44. № 10. P. 1010-1015.
Nie, W., Wang, J., Zeng, J. et al.
Adjunctive interleukin-2 for the treatment of drug-susceptible tuberculosis: a randomized control trial in China.Infection 50, 413–421 (2022). https://doi.org/10.1007/s15010-021-01698-3
Nilsson, M. S., Hallner, A., Brune, M. et al.
Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.Human Vaccines & Immunotherapeutics, 16(1), 109–111.
Nina Le Bert, Hannah E Clapham, Anthony T Tan et al. PDF
bioRxiv. Cold Spring Harbor Laboratory. – 2020, doi: https://doi.org/10.1101/2020.11.25.399139
Nirschl CJ, Brodkin HR, Hicklin DJ et al.
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression.Cancer Immunol Res. 2022 May 3;10(5):581-596. doi: 10.1158/2326-6066.CIR-21-0831.
Noguchi G., Ota J, Ishigaki H. et al.
A Case of Retroperitoneal Angiosarcoma Effectively Treated With Recombinant interleukin-2.Case Reports Nihon Hinyokika Gakkai Zasshi. 2012 Nov;103(6):697-703. doi: 10.5980/jpnjurol.103.697.
В соответствии с п. 1 ст. 64 Федерального закона от 12.04.2010 № 61-ФЗ "Об обращении лекарственных средств" лекарственные препараты, находящиеся в обращении на территории Российской Федерации, подлежат мониторингу безопасности в целях выявления возможных негативных последствий их применения, предупреждения пациентов и их защиты от применения таких препаратов.